In RCC patients from the RCC_2020 cohort, contrasting ICB treatment responses and prognoses were observed in the high SLC1A5 expression group after ai-PD-1 and EVEROLIM treatment (Supplementary Figures 2E, 2F and 3E, 3F). Here, SLC1A5 is linked to renal cell carcinoma.